Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sell-Side Takes Community Health's Vital Signs After Sickly Q2 Preview Release

CYH, HCA

One bull still stands for Community Health Systems (NYSE: CYH), even after management’s preview of second-quarter earnings on Wednesday shocked and disappointed most investors.

The news also came just a day after HCA Healthcare Inc (NYSE: HCA) reported a miss for Q2 and EPS guidance for the year below consensus, since which its shares are down over 5.5 percent.

Oppenheimer’s Michael Wiederhorn reiterated an Outperform rating on the stock, which dropped 15.5 percent on Thursday’s open to $7.15.

“The hospital fundamentals clearly remain challenging ... and we expect more information when they report results on August 1st,” said Wiederhorn.

Community Health expects Q2 adjusted EPS to come in at negative $0.25 and sales of $4.144 billion–4.05 billion, compared to the Street’s positive $0.06 and $4.08 billion estimates.

Revenues at the low end of guidance would be a 10-percent reduction year over year.

Same-store adjusted admissions are now expected to be negative 2.5 percent for the quarter, and between negative 2–1 percent for the year. Previously, the company had guided for 0–1.5 percent.

Community Health attributed the downward revisions to lower-than-expected volumes.

Despite the rating, the most bullish statement from Wiederhorn seemed to be that he will follow up with more color and estimate revisions after the final report.

Keep up with earnings season and analyst coverage in real-time with Benzinga Pro.

Related Links:

Samsung, Amazon — Everyone Is Getting Into Pharmaceuticals

Your Guide To 2017's Emerging Pharmaceuticals Catalysts



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today